XML 173 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Operating Segments | 12 Months Ended
--- | ---
Dec. 31, 2024
Operating Segments [Abstract] |
OPERATING SEGMENTS |
NOTE 23:- | OPERATING SEGMENTS
The Company applies the principles of IFRS 8, “Operating Segments” (“IFRS 8”), regarding operating segments. The segment reporting is based on internal management reports of the Company’s management, which are regularly reviewed by the Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company’s management determined that it has two reportable segments – (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company’s operation); and (2) online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. Segment performance (segment income (loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items that are allocated directly to the segments and items that can be allocated on a reasonable basis. The review of the CODM is carried out according to the results of the segment’s performance. His review does not include certain expenses that are not related specifically to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating results in financial statements. The Group’s CODM is the CEO of the Company.
|  | Year ended December 31, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,306 |  |  | $ | 1,306 |
Total |  |  | - |  |  |  | 1,306 |  |  |  | 1,306 |
Segment loss (gain) |  |  | 4,873 |  |  |  | 2,443 |  |  |  | 7,316 |
Equity losses from the investment in MitoCareX |  |  |  |  |  |  |  |  |  |  | 429 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (259 | )
Tax income |  |  |  |  |  |  |  |  |  |  | (14 | )
Loss |  |  |  |  |  |  |  |  |  |  | 7,472 |
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 1,456 |  |  |  | 6,815 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
Drug Development Segment In the year ended December 31, 2024, the Company recognized other income in the amount of $1,288 as a result of a sale of an intangible asset. Online Sales Segment In the years ended December 31, 2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).
|  | Year ended December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,347 |  |  | $ | 1,347 |
Total |  |  | - |  |  |  | 1,347 |  |  |  | 1,347 |
Segment loss |  |  | 8,405 |  |  |  | (118 | ) |  |  | 8,287 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 109 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (5,818 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 14 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,592 |
|  | As of December 31, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 8,407 |  |  | $ | 1,764 |  |  | $ | 10,171 |
Segment Liabilities |  | $ | 1,194 |  |  | $ | 226 |  |  | $ | 1,420 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration